KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Equity Ratio (2016 - 2025)

NovoCure's Equity Ratio history spans 12 years, with the latest figure at 0.42 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 45.82% year-over-year to 0.42; the TTM value through Dec 2025 reached 0.42, up 45.82%, while the annual FY2025 figure was 0.42, 45.82% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.42 at NovoCure, up from 0.25 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.42 in Q4 2025 and bottomed at 0.25 in Q3 2025.
  • The 5-year median for Equity Ratio is 0.35 (2023), against an average of 0.34.
  • The largest annual shift saw Equity Ratio crashed 48.23% in 2021 before it skyrocketed 45.82% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.36 in 2021, then rose by 2.77% to 0.37 in 2022, then fell by 14.57% to 0.32 in 2023, then decreased by 8.22% to 0.29 in 2024, then surged by 45.82% to 0.42 in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Equity Ratio are 0.42 (Q4 2025), 0.25 (Q3 2025), and 0.28 (Q2 2025).